Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 1.8.1.9 extracted from

  • Lu, J.; Chew, E.H.; Holmgren, A.
    Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide (2007), Proc. Natl. Acad. Sci. USA, 104, 12288-12293.
    View publication on PubMedView publication on EuropePMC

Inhibitors

Inhibitors Comment Organism Structure
arsenic trioxide irreversible. Both the N-terminal redox-active dithiol and the C-terminal selenothiol-active site of reduced TrxR may participate in the reaction with the inhibitor. The inhibition of MCF-7 cell growth by arsenic trioxide is correlated with irreversible inactivation of thioredoxin reductase, which subsequently led to thioredoxin oxidation Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
MCF-7 cell
-
Homo sapiens
-